Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 2/20 | 0.52 |
| ▸ | JAK2 | O60674 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 7/20 | 0.43 |
| ▸ | JAK3 | P52333 | 4/20 | 0.43 |
| ▸ | BRDT | Q58F21 | 3/20 | 0.43 |
| ▸ | BRD2 | P25440 | 1/20 | 0.43 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 3/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 2/20 | 0.43 |
| ▸ | SIK1 | P57059 | 2/20 | 0.42 |
| ▸ | SIK2 | Q9H0K1 | 2/20 | 0.42 |
| ▸ | SIK3 | Q9Y2K2 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17640327 | 0.80 | JAK2 (0.49) | AXLJAK2BRD4JAK3BRDT | |
| SCHEMBL17640273 | 0.80 | AXL (0.48) | AXLJAK2KDM4EJAK3FLT3 | |
| SCHEMBL18921933 | 0.78 | AXL (0.52) | AXLJAK2KDM4EBRD4JAK3 | |
| SCHEMBL12965720 | 0.77 | AXL (0.46) | AXLJAK2FLT3 | |
| SCHEMBL21677035 | 0.75 | AXL (0.47) | AXLJAK2BRD4JAK3BRDT | |
| SCHEMBL15805375 | 0.74 | JAK2 (0.45) | AXLJAK2KDM4EBRD4JAK3 | |
| SCHEMBL29469944 | 0.73 | AXL (0.55) | AXLJAK2KDM4EBRD4JAK3 | |
| SCHEMBL15805447 | 0.73 | JAK2 (0.49) | AXLJAK2JAK3FLT3BTK | |
| SCHEMBL21677036 | 0.73 | CLK1 (0.45) | AXLJAK2KDM4EBRD4JAK3 | |
| SCHEMBL15805363 | 0.73 | AXL (0.47) | AXLJAK2BTKSIK1SIK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9669028-B2 | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2017-06-06 | — | — | US | claimed |
| US-8791112-B2 | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2014-07-29 | — | — | US | claimed |
| US-20130102586-A1 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2013-04-25 | — | — | US | claimed |
| US-9962382-B2 | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2018-05-08 | — | — | US | disclosed |
| US-9962382-B2 | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2018-05-08 | — | — | US | disclosed |
| US-9669028-B2 | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-9669028-B2 | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160074395-A1 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2016-03-17 | — | — | US | disclosed |
| US-20160060261-A1 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ARRIEN PHARMACEUTICALS LLC | 2016-03-03 | — | — | US | disclosed |
| US-20160060261-A1 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ARRIEN PHARMACEUTICALS LLC | 2016-03-03 | — | — | US | disclosed |
| US-9187473-B2 | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187473-B2 | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140309211-A1 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140309211-A1 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2014-10-16 | — | — | US | disclosed |
| US-8791112-B2 | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2014-07-29 | — | — | US | disclosed |
| US-8791112-B2 | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2014-07-29 | — | — | US | disclosed |
| US-20130102586-A1 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102586-A1 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2012135631-A1 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ARRIEN PHARMAEUTICALS LLC (US) | 2012-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060261-A1 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MAP3K9, MAP3K19, MAP4K2 | AXL 918/4885JAK2 360/4885KDM4E 1131/4885 |
| US-20160074395-A1 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MAP3K9, MAP3K19, MAP4K2 | AXL 918/4885JAK2 360/4885KDM4E 1131/4885 |
| US-20140309211-A1 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MAP3K9, MAP3K19, MAP4K2 | AXL 918/4885JAK2 360/4885KDM4E 1131/4885 |
| US-20130102586-A1 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MAP3K9, MAP3K19, MAP4K2 | AXL 918/4885JAK2 360/4885KDM4E 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.